department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Skyrizi · pharmadog

pharmadog
drugs
Skyrizi

drug

patient view →

risankizumab

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

annual revenue · 2024–2024peak $11.7B

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 6 investigational indications.

indications

investigational

IBD (Crohn's + UC)

all catalysts(23)

approval · 23

view all 23 catalysts →

News(0)

no news has mentioned this drug yet

brand

Skyrizi

generic

risankizumab-rzaa

MOA

12.1 Mechanism of Action Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Risankizumab-rzaa inhibits the release of pro-inflammatory cytokines and chemokines.

indication

Psoriatic Arthritis

phase

marketed

approved

2019-04-23

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

$ABBV255.25-2.23%

🐶 often sniffed alongside

top 3

drugSKYRIZI92 co-mentions · 23 sources
tagApproval92 co-mentions · 23 sources
company$ABBVAbbVie Inc.46 co-mentions · 23 sources

Trials studying risankizumab

phase3A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Diseaserecruitingn=530
phase3A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumabactive not recruitingn=573
phase3A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitisrecruitingn=120
phase2Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Diseaserecruitingn=540
phase3A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Diseaserecruitingn=110
phase3Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Responserecruitingn=600
phase4A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Diseasecompletedn=10
phase4A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)completedn=393

more trials →